[18F]FDG PET/CT features for the molecular characterization of primary breast tumors

Antunovic, Lidija; Gallivanone, Francesca; Sollini, Martina; Sagona, Andrea; Invento, Alessandra; Manfrinato, Giulia; Kirienko, Margarita; Tinterri, Corrado; Chiti, Arturo; Castiglioni, Isabella

doi:10.1007/s00259-017-3770-9

Cited by 66 publications

(56 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Key to this discrepancy seems to be the partial volume effect. Similar to our study, Antunovic et al performed partial volume correction on their metric SUV data and similarly missed an association of size and metabolism [48]. We believe partial volume correction is a crucial feature which is not discussed broadly enough, but is essential for future studies and clinically relevant for therapy monitoring [49].…”

Section: Discussionsupporting

confidence: 80%

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2− Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT

et al. 2019

View full text Add to dashboard Cite

Purpose: In PIK3CA mutant breast cancer, downstream hyperactivation of the PI3K/AKT/mTOR pathway may be associated with increased glycolysis of cancer cells. The purpose of this study was to investigate the functional association of PIK3CA mutational status and tumor glycolysis in invasive ER+/HER2− early breast cancer. Procedures: This institutional review board-approved retrospective study included a dataset of 67 ER+/HER2− early breast cancer patients. All patients underwent 2-deoxy-2-[ 18 F]fluoro-Dglucose positron emission tomography/X-ray computed tomography ([ 18 F]FDG PET/CT) and clinico-pathologic assessments as part of a prospective study. For this retrospective analysis, pyrosequencing was used to detect PIK3CA mutations of exons 4, 7, 9, and 20. Tumor glucose metabolism was assessed semi-quantitatively with [ 18 F]FDG PET/CT using maximum standardized uptake values (SUV max). SUV max values were corrected for the partial volume effect, and metabolic tumor volume was calculated using the volume of interest automated lesion growing function 2D tumor size, i.e., maximum tumor diameter was assessed on concurrent pretreatment contrast-enhanced magnetic resonance imaging. Results: PIK3CA mutations were present in 45 % of all tumors. Mutations were associated with a small tumor diameter (p G 0.01) and with low nuclear grade (p = 0.04). Glycolytic activity was positively associated with nuclear grade (p = 0.01), proliferation (p = 0.002), regional lymph node metastasis (p = 0.015), and metabolic tumor volume (p = 0.001) but not with tumor size/T-stage. Heinrich Magometschnigg and Katja Pinker as well as Peter Dubsky and Martin Filipits contributed equally to this work.

show abstract

Section: Discussionsupporting

confidence: 80%

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2− Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In some breast cancer subtypes (luminal A), FDG uptake is physiologically influenced by both the features of the tumor and hormonal fluctuations during the menstrual cycle (15). In addition to the FDG uptake value, advanced imaging features such as histogram of FDG-PET can be used to separate molecular and histological subtypes (16,17). It has also been reported that FDG-PET radiomics are associated with various tumor aspects (namely, Ki67, pCR after NAC and risk of recurrence) and may potentially become unique pretreatment biomarkers of diagnosis and prognosis (18).…”

Section: Fluorodeoxyglucose Pet and Tumor Biologymentioning

confidence: 99%

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Ming

Qian

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is a major disease with high morbidity and mortality in women worldwide. Increased use of imaging biomarkers has been shown to add more information with clinical utility in the detection and evaluation of breast cancer. To date, numerous studies related to PET-based imaging in breast cancer have been published. Here, we review available studies on the clinical utility of different PET-based molecular imaging methods in breast cancer diagnosis, staging, distant-metastasis detection, therapeutic and prognostic prediction, and evaluation of therapeutic responses. For primary breast cancer, PET/MRI performed similarly to MRI but better than PET/CT. PET/CT and PET/MRI both have higher sensitivity than MRI in the detection of axillary and extra-axillary nodal metastases. For distant metastases, PET/CT has better performance in the detection of lung metastasis, while PET/MRI performs better in the liver and bone. Additionally, PET/CT is superior in terms of monitoring local recurrence. The progress in novel radiotracers and PET radiomics presents opportunities to reclassify tumors by combining their fine anatomical features with molecular characteristics and develop a beneficial pathway from bench to bedside to predict the treatment response and prognosis of breast cancer. However, further investigation is still needed before application of these modalities in clinical practice. In conclusion, PET-based imaging is not suitable for early-stage breast cancer, but it adds value in identifying regional nodal disease and distant metastases as an adjuvant to standard diagnostic imaging. Recent advances in imaging techniques would further widen the comprehensive and convergent applications of PET approaches in the clinical management of breast cancer.

show abstract

“…Additionally, PET/ CT is clinically indicated only for stage III breast cancer patients and so stage I and II breast cancers, which represent the majority, have been excluded from the analysis of these retrospective datasets. Radiogenomic analyses to date have principally focused on metabolic activity parameters of the primary tumor, most commonly via analysis of the maximum standardized uptake values, but also via analysis of the metabolic tumor volume and total lesion glycolysis (30)(31)(32)(33)(34)(35)(36)(37)(38)(39). While more advanced metrics such as histogram-based features have only recently been explored (30).…”

Section: Fdg Pet/ctmentioning

confidence: 99%

Breast Cancer Radiogenomics: Current Status and Future Directions

Grimm

Mazurowski

2020

Academic Radiology

View full text Add to dashboard Cite

[18F]FDG PET/CT features for the molecular characterization of primary breast tumors

Abstract: Our results suggest a complementary role of standard PET imaging parameters and advanced imaging features for the in vivo biological characterization of BC lesions.

Cited by 66 publications

References 43 publications

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2− Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2− Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Breast Cancer Radiogenomics: Current Status and Future Directions

Contact Info

Product

Resources

About